Adjei AL, Gupta PK. Inhalation Delivery of Therapeutic Peptides and Proteins. New York: Marcel Dekker, 1997.

Byron PR. Respiratory Drug Delivery. Boca Raton: CRC Press, 1990.

Derendorf H, Hochhaus G. Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Boca

Raton: CRC Press, 1995. Fuchs NA. Mechanics of Aerosols. Minneola: Dover Press, 1964.

Ganderton D, Jones T. Drug Delivery to the Respiratory Tract. New York: VCH/Ellis Horwood, 1987.

Gehr P, Heyder J. Particle-Lung Interactions. New York: Marcel Dekker, 2000. Hickey AJ. Pharmaceutical Inhalation Aerosol Technology. 2nd ed. New York: Marcel Dekker, 2004.

Hickey AJ. Inhalation Aerosols. 2nd ed. New York: Informa Healthcare, 2007.

Lefebvre AH. Atomization and Sprays. New York: Hemisphere Publishing Corporation, 1989.

Newman SP. Deposition and Effects of Inhalation Aerosols. Lund, Sweden: AB DRACO

(subsidiary to ASTRA), 1983. Purewal TS, Grant DJW. Metered Dose Inhaler Technology. Buffalo Grove: Interpharm Press, Inc., 1998.

Reist P. Aerosol Science and Technology. 2nd ed. New York: McGraw-Hill, 1993. REFERENCES

1. Sciarra JJ. Pharmaceutical aerosols. In: Lachman L, Lieberman HA, Kanig JL, eds. The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea and Febiger, 1970:605-638.

2. Thiel CG. From Susie's Question to CFC Free: An Inventor's Perspective on Forty Years of MDI Development and Regulation. Respiratory Drug Delivery V. Phoenix, AZ: Davis Healthcare International Publishing, LLC, 1996:115-123.

3. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom catalyzed destruction of ozone. Nature 1974; 249:1810.

4. Montreal Protocol 1987. Montreal protocol on substances that deplete the ozone layers, 1987.

5. Hickey AJ, Dunbar CA. A new millenium for inhaler technology. Pharm Technol 1997; 21:116-125.

6. Gonda I. Targeting by deposition. In: Hickey AJ, ed. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, Inc., 1992:61-82.

7. Allen T. Particle Size Measurement. 4th ed. London: Chapman and Hall, 1993.

8. Raabe OG. Aerosol aerodynamic size conventions for inertial sampler calibration. J Air Pollut Control Assoc 1976; 26:856-860.

9. Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. 2nd ed. New York: John Wiley and Sons, Inc, 1999.

10. Ferron GA, Oberdorster G, Henneberg R. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth. J Aerosol Med 1989; 2:271-283.

11. Hickey AJ, Martonen TB. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm Res 1993; 10:1-7.

12. Weibel ER. Morphometry of the Human Lung. Berlin: Springer Verlag, 1963.

13. Horsfield K, Woldenberg MJ. Branching ratio and growth of tree-like structures. Respir Physiol 1986; 63:97-107.

14. Findeisen W. Über das Absetzen kleiner, in der Luft suspendierten Teilchen in der menschlichen Lunge bei der Atmung. Arch Ges Physiol 1935; 236:367.

15. Martonen TB, Katz I, Fults K, et al. Use of analytically defined estimates of aerosol respirable fraction to predict lung deposition patterns. Pharm Res 1992; 9:1634-1639.

16. Hatch TF, Gross P. Physical Factors in Respiratory Deposition of Aerosols. Pulmonary Deposition and Retention of Inhaled Aerosols. New York: Academic Press, 1964:27-43.

17. Chaffee VW. Surgery of laboratory animals. In: Melby EC, Altman NH, eds. Handbook of Laboratory Animal Science. Cleveland: CRC Press, Inc., 1974:233-273.

18. Phalen RF, Oldham MJ. Tracheobronchial airway structure as revealed by casting techniques. Am Rev Respir Dis 1983; 128:S1-S4.

19. Landahl HD. On the removal of air-borne droplets by the human respiratory tract. I. The Lung. Bull Math Biophys 1950; 12:43.

20. ICRP P. Human respiratory tract model for radiological protection. Ann ICRP 1994; 24:1-3.

21. McCusker K, Hiller FC, Wilson JD, et al. Aerodynamic sizing of tobacco smoke particulate from commercial cigarettes. Arch Environ Health 1983; 38:215-218.

22. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 1983; 125:S59-S65.

23. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sei 1986; 75:433-438.

24. Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J Pharm Sei 1988; 77:340-348.

25. Hochhaus G, Suarez S, Gonzalez-Rothi RJ, et al. Pulmonary Targeting of Inhaled Glucocorticoids: How Is it Influenced by Formulation. Respiratory Drug Delivery VI. . Hilton Head, SC: Interpharm Press, Inc., 1998:45-52.

26. Hickey AJ. Lung deposition and clearance of pharmaceutical aerosols: what can be learned from inhalation toxicology and industrial hygiene? Aerosol Sei Technol 1993; 18:290-304.

27. Hickey AJ, Mansour HM. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. In: Rathbone MJ, Hadgraft J, Roberts MS, et al. (eds.), Modified-Release Drug Delivery Technology, Vol 2, Drugs and the Pharmaceutical Sciences Series, 2nd ed. New York: Informa Healthcare, 2008: 573-602.

28. Dunbar C, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Part 1998; 16:7^15.

29. Chow AHL, Tong HHY, Chattopadhyay P, et al. Particle engineering for pulmonary drug delivery. Pharm Res 2007; 24:411^137.

30. Mosen K, Backstrom K, Thalberg K, et al. Particle formation and capture during spray-drying of inhalable particles. Pharm Dev Technol 2004; 9:409^117.

31. Vidgren MT, Vidgren PA, Paronen TP. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. Int J Pharm 1987; 35:139-144.

32. Van Oort MM, Sacchetti M. Spray-drying and supercritical fluid particle generation techniques. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. 2nd ed. New York: Informa Healthcare, 2007:307-346.

33. Tong HHY, Chow AHL. Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing. KONA Powder Part 2006; 24:27-40.

34. Tom JW, Debendetti PG. Particle formation with supercritical fluids—a review. J Aerosol Sei 1991; 22:555-584.

35. York P, Kompella UB, Shekunov BY. Supercritical Fluid Technology for Drug Product Development. 1st ed. New York: CRC Press, 2004.

36. Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sei 2004; 22:1-17.

37. Shekunov BY. Production of powders for respiratory drug delivery. In: York P, Kompella UB, Shekunov BY, eds. Supercritical Fluid Technology for Drug Product Development. New York: Marcel Dekkar, 2004:247-282.

38. Shekunov BY, Chattopadhyay P, Seitzinger J, et al. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 2006; 23:196-204.

39. Shekunov BY, Feeley JC, Chow AHL, et al. Physical properties of supercritically-processed and micronised powders for respiratory drug delivery. KONA Powder Part 2002; 20:178-187.

40. Shekunov BY, Feeley JC, Chow AHL, et al. Aerosolisation behaviour of micronised and supercritically processed powders. J Aerosol Sei 2003; 34:553-568.

41. Schiavone H, Palakodaty S, Clark A, et al. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 2004; 281:55-66.

42. Velaga SP, Bergh S, Carlfors J. Stability and aerodynamic behaviour of glucocorticoid particles prepared by a supercritical fluids process. Eur J Pharm Sei 2004; 21:501-509.

43. Lobo JM, Schiavone H, Palakodaty S, et al. SCF-engineered powders for delivery of budesonide from passive DPI devices. J Pharm Sei 2005; 94:2276-2288.

44. Dalby RN. Halohydrocarbons, pharmaceutical usesln: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, Inc., 1993:161-180.

45. Atkins P. Physical Chemistry. 5th ed. New York: W.H. Freeman and Company, 1994.

46. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.

47. Clark AR. Metered Atomisation for Respiratory Drug Delivery [PhD thesis]. Loughborough University of Technology, U.K., 1991.

48. Dunbar CA, Watkins AP, Miller JF. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J Aerosol Med 1997; 10:351-368.

49. Dunbar CA, Watkins AP, Miller JF. A theoretical investigation of the spray issued from a pMDI. Atomization Sprays 1997; 7:417^136.

50. Sirand C, Varlet JP, Hickey AJ. Aerosol-filling equipment for the preparation of pressurized pack pharmaceutical formulations. In: Hickey AJ, ed. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, Inc, 2004:311-343.

51. U.S. Food and Drug Administration. Use of ozone-depleting substances; removal of essential-use designation. U.S. Food and Drug Administration, 2005.

52. Hickey AJ, Concessio NM, Van Oort MM, et al. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol 1994; 18:58-64, 82.

53. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sei 2007; 96:1282-1301.

54. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sei 2007; 96:1302-1319.

55. Louey MD, Van Oort M, Hickey AJ. Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion. J Aerosol Sei 2006; 37:1520-1531.

56. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing. J Aerosol Med 1993; 6:99-110.

57. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5:506-508.

58. Rubin LD. Intal (Cromolyn Sodium) A Monograph. 1st ed. Bedford, MA: Fisons Corporation, 1973.

59. Marple VA. Simulation of respirable penetration characteristics by inertial impaction. J Aerosol Sei 1978; 9:125-134.

60. Vaughan NP. The Andersen impactor: calibration, wall losses and numerical simulation. J Aerosol Sei 1989; 20:67-90.

61. Berglund RN, Liu BYH. Generation of monodisperse aerosol standards. Environ Sei Technol 1973; 7:147-152.

62. Byron PR, Hickey AJ. Spinning-disk generation and drying of monodisperse solid aerosols with output concentrations sufficient for single-breath inhalation studies. J Pharm Sei 1987; 76:60-64.

63. Vervaet C, Byron PR. Polystyrene microsphere spray standards based on CFC-free inhaler technology. J Aerosol Med 2000; 13:105-115.

64. Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers Monograph. USP 29-NF 24 The United States Pharmacopoeia and The National Formulary: The Official Compendia of Standards. Rockville, MD: The United States Pharmacopeial Convention, Inc, 2006:2617-2636.

65. Kamiya A, Sakagami M, Hindle M, et al. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and next generation pharmaceutical impactors and their USP methods. J Pharm Sei 2004; 93:1828-1837.

66. Marple VA, Olson BA, Santhanakrishnan K, et al. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part IE. Extension of archival calibration to 15 L/min. J Aerosol Med 2004; 17:335-343.

67. Leung K, Louca E, Gray M, et al. Use of the next generation pharmaceutical impactor for particle size distribution measurements of live viral aerosol vaccines. J Aerosol Med 2005; 18:414-426.

68. Myrdal PB, Mogalian E, Mitchell J, et al. Application of heated inlet extensions to the TSI 3306/3321 system: comparison with the Andersen cascade impactor and next generation impactor. J Aerosol Med 2006; 19:543-554.

69. Berg E, Svensson JO, Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med 2007; 20:97-104.

70. Mitchell JP, Nagel MW, Wiersema KJ, et al. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer. AAPS PharmSciTech 2003; 4:E54.

71. Guo C, Gillespie SR, Kauffman J, et al. Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor. J Pharm Sei 2007; 97(8):3321-3334.

72. Mathias NR, Yamashita F, Lee VHL. Respiratory epithelial cell culture models for evaluation of ion and drug transport. Adv Drug Deliv Rev 1996; 22:215-249.

73. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001; 6:367-375.

74. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med 2005; 18:137-182.

75. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 58:1030-1060.

76. Foster KA, Oster CG, Mayer MM, et al. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998; 243:359-366.

77. Brack A, Abu-Dahab R, Borchard G, et al. Lectin-functionalized liposomes for pulmonary drug delivery: interaction with human alveolar epithelial cells. J Drug Target 2001; 9:241.

78. Ehrhardt C, Fiegel J, Fuchs S, et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J Aerosol Med 2002; 15:131-139.

79. Hermanns MI, Unger RE, Kehe K, et al. Lung epithelial cell lines in coculture with human microvascular endothelial cells: development of an alveolo-capillary barrier in vitro. Lab Invest 2004; 84:736-752.

80. Foster KA, Avery ML, Yazdanian M, et al. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 2000; 208:1-11.

81. Florea BI, van der Sandt ICJ, Schrier SM, et al. Evidence of p-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br J Pharm 2001; 134:1555-1563.

82. Borchard G, Cassara ML, Roemele PE, et al. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sei 2002; 91:1561-1567.

83. Florea BI, Cassara ML, Junginger HE, et al. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003; 87:131-138.

84. Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 2005; 60:193-205.

85. Grainger CI, Greenwell LL, Lockley DJ, et al. Culture of Calu-3 Cells at the air-water interface provides a representative model of the airway epithelial barrier. Pharm Res 2006; 23:1482-1490.

86. Ehrhardt C, Kneuer C, Bies C, et al. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther 2005; 18:165-170.

87. Ehrhardt C, Kneuer C, Laue M, et al. 16HBE14o-human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolin-1. Pharm Res 2003; 20:545-551.

88. Manford F, Tronde A, Jeppsson AB, et al. Drug permeability in 16HBE14o-airway cell layers correlates with absorption from the isolated perfused rat lung. Eur J Pharm Sei 2005; 26:414-420.

89. Robinson PC, Voelker DR, Mason RJ. Isolation and culture of human alveolar type-II epithelial cells. Characterization of their phospholipid secretion. Am Rev Respir Dis 1984; 130:1156-1160.

90. Elbert KJ, Shafer UF, Shafers HJ, et al. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm Res 1999; 16:601-608.

91. Fuchs S, Hollins AJ, Laue M, et al. Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res 2003; 311:31^45.

92. Bur M, Huwer H, Lehr CM, et al. Assessment of transport rates of proteins and peptides across primary human alveolar epithelial cell monolayers. Eur J Pharm Sei 2006; 28:196-203.

93. Lin HC, Li H, Cho HJ, et al. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sei 2007; 96:341-350.

94. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol 2005; 32:281-289.

95. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products-Chemistry, Manufacturing, and Controls Documentation. Washington, D.C.: U.S. FDA, CDR, 2002:45.

96. U.S. Food and Drug Administration. Draft Guidance for Industry-Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation. Washington, D.C.: FDA, 1998.

97. European Pharmacopeia. Preparations for Inhalation. European Pharmacopeia, 2001.

98. Evans R. Determination of drug particle size and morphology using optical microscopy. Pharm Technol 1993; 17:146-152.

99. Milosovich SM. Particle-size determination via cascade impaction. Pharm Technol 1992; 16:82-86.

100. Atkins PJ. Aerodynamic particle-size testing-4mpinger methods. Pharm Technol 1992; 16:26-32.

101. Jager PD, DeStefano GA, McNamara DP. Particle-size measurement using right-angle light scattering. Pharm Technol 1993; 17:102-120.

102. Ranucci JA, Chen F-C. Phase Doppler anemometry: a technique for determining aerosol plume-particle size and velocity. Pharm Technol 1993; 17:62-74.

103. Ranucci J. Dynamic plume-particle size analysis using laser diffraction. Pharm Technol 1992; 16:109-114.

104. Niven RW. Aerodynamic particle size testing using a time-of-flight aerosol beam spectrometer. Pharm Technol 1993; 72-78.

105. Gorman WG, Carroll FA. Aerosol particle-size determination using laser holography. Pharm Technol 1993; 17:34-37.

106. Hickey AJ, Evans RM. Aerosol generation from propellant-driven metered dose inhalers. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker, Inc., 1996:417^139.

107. Dunbar CA, Hickey AJ. Selected parameters affecting characterization of nebulized aqueous solutions by inertial impaction and comparison with phase-Doppler analysis. Eur J Pharm Biopharm 1999; 48:171-177.

108. Leong BKJ, ed. Inhalation Toxicology and Technology. Ann Arbor: Ann Arbor Science, 1981.

109. Concessio NM, Oort MMV, Knowles M, et al. Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res 1999; 16:828-834.

110. Newman S, Wilding IR, Hirst P. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000; 208:49-60.

111. Meyer T, Brand P, Ehlich H, et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med Deposition Clear Eff Lung 2004; 17:43-49.

112. Bondesson E, Asking L, Borgstrom L, et al. In vitro and in vivo aspects of quantifying intrapulmonary deposition of a dry powder radioaerosol. Int J Pharm 2002; 232:149-156.

113. Sebti T, Pilcer G, Van Gansbeke B, et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm 2006; 64:26-32.

114. Eberl S, Chan HK, Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J Aerosol Med Deposition Clear Eff Lung 2006; 19:8-20.

115. Dolovich M. Lung dose, distribution, and clinical response to therapeutic aerosols. Aerosol Sei Technol 1993; 18:230-240.

116. Vidgren M, Arppe J, Vidgren P, et al. Pulmonary deposition and clinical response of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose powder inhaler. Pharm Res 1994; 11:1320-1324.

117. Vidgren M, Waldrep JC, Arppe J, et al. Study of 99mTechnetium-labeled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm 1995; 115:209-216.

118. Vidgren MT, Karkkainen A, Paronen P, et al. Respiratory tract deposition of 99mTc-labelled drug particles administered via a dry powder inhaler. Int J Pharm 1987; 39:101-105.

119. Vidgren M, Arppe J, Vidgren P, et al. Pulmonary deposition of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose powder inhaler. STP Pharm Sei 1994; 4:29-32.

120. Pitcairn GR, Hooper G, Luria X, et al. A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler. Adv Drug Deliv Rev 1997; 26:59-67.

121. Pitcairn GR, Lim J, Hollingworth A, et al. Scintigraphic assessment of drug delivery from the ultrahaler dry powder inhaler. J Aerosol Med 1997; 10:295-306.

122. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000; 16:178-183.

123. Newman SP, Pitcairn GR, Hirst PH, et al. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003; 55:851-867.

124. Kaliner MA, Barnes PJ, Persson CGA. Asthma, Its Pathology and Treatment. New York: Marcel Dekker, 1991.

125. Adjei A, Garren J. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 1990; 7:565-569.

126. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35:235-247.

127. White S, Bennett DB, Cheu S, et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005; 7:896-906.

128. NDA 21-868/Exubera US Package Insert. New York, NY: Pfizer Labs, 2006:1-24.

129. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7:49-75.

130. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6:67-74.

Quit Smoking For Good

Quit Smoking For Good

Quit smoking for good! Stop your bad habits for good, learn to cope with the addiction of cigarettes and how to curb cravings and begin a new life. You will never again have to leave a meeting and find a place outside to smoke, losing valuable time. This is the key to your freedom from addiction, take the first step!

Get My Free Ebook

Post a comment